Can a genomic signature help select patients more accurately for DDR therapies?
What are Gritstone up to behind the scenes and where are they headed in the near-term?
Can AI and deep learning help us re-program genetic defects with RNA therapies?
What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?
How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Some intriguing convergence from two recent conferences offers new insights from an AI perspective
new approaches to applying translational research to the clinic in oncology R&D
